- Home
- MHF vs SGMT Comparison
MHF vs SGMT Comparison
Compare MHF & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHF
- SGMT
- Stock Information
- Founded
- MHF 1988
- SGMT 2006
- Country
- MHF United States
- SGMT United States
- Employees
- MHF N/A
- SGMT N/A
- Industry
- MHF Finance/Investors Services
- SGMT
- Sector
- MHF Finance
- SGMT
- Exchange
- MHF Nasdaq
- SGMT Nasdaq
- Market Cap
- MHF 148.8M
- SGMT 230.3M
- IPO Year
- MHF N/A
- SGMT 2023
- Fundamental
- Price
- MHF $7.41
- SGMT $6.36
- Analyst Decision
- MHF
- SGMT Strong Buy
- Analyst Count
- MHF 0
- SGMT 7
- Target Price
- MHF N/A
- SGMT $26.57
- AVG Volume (30 Days)
- MHF 57.2K
- SGMT 516.1K
- Earning Date
- MHF 01-01-0001
- SGMT 11-12-2025
- Dividend Yield
- MHF 4.29%
- SGMT N/A
- EPS Growth
- MHF N/A
- SGMT N/A
- EPS
- MHF N/A
- SGMT N/A
- Revenue
- MHF N/A
- SGMT N/A
- Revenue This Year
- MHF N/A
- SGMT N/A
- Revenue Next Year
- MHF N/A
- SGMT N/A
- P/E Ratio
- MHF N/A
- SGMT N/A
- Revenue Growth
- MHF N/A
- SGMT N/A
- 52 Week Low
- MHF $5.92
- SGMT $1.73
- 52 Week High
- MHF $6.79
- SGMT $11.41
- Technical
- Relative Strength Index (RSI)
- MHF 71.59
- SGMT 32.61
- Support Level
- MHF $7.11
- SGMT $6.77
- Resistance Level
- MHF $7.50
- SGMT $7.35
- Average True Range (ATR)
- MHF 0.14
- SGMT 0.44
- MACD
- MHF 0.05
- SGMT -0.04
- Stochastic Oscillator
- MHF 87.50
- SGMT 4.46
About MHF Western Asset Municipal High Income Fund Inc.
Western Asset Municipal High Income Fund Inc is a diversified closed-end management investment company. The company's objective is to seek high current income exempt from federal income taxes. It invests predominantly in intermediate and long-term municipal debt securities issued by state and local governments.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.